Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Expert consensus suggests considering pharmacotherapy when there is: Significant weight regain from nadir weight BMI 27 kg/m with obesity-related comorbidities or BMI 30 kg/m Absence of anatomical complications requiring surgical revision Adequate adherence to nutritional and behavioral recommendations Patient willingness to engage in long-term pharmacotherapy The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines emphasize that pharmacologic therapy should complement, not replace, lifestyle interventions and ongoing bariatric surgical follow-up
By activating GLP-1 receptors in the brain, semaglutide helps to increase the production of satiety hormones and reduce hunger signals, making it easier for individuals to adhere to a healthy eating plan
One of those medications, Wegovy, is also FDA-approved for the treatment of cardiovascular disease
Cynthia Maxwell and reviewed by First Exposure Medical Review Team
95% CI [0.150.92])
US$ 21.70
US$ 28.81
US$ 22.38
US$ 25.62
US$ 21.72
US$ 23.85
US$ 24.86
